The Use of Liraglutide in Brain Death

NCT03672812 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide affects inflammation in individuals who have been declared brain dead.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 50 people

Who can join Ages 18+ · all sexes

Timeline Started 2018-09 · est. completion 2022-02

Where 1 site · Brazil

What this study is testing ClinicalTrials.gov NCT03672812 ↗

Description as written by the study sponsor.

There is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood. Observational studies suggest that the use of target-guided therapies has a beneficial effect in reducing the rate of donor loss due to cardiac arrest and increasing the rate of donor-picked organs, which will be tested through the randomized clinical trial. However, no study so far has directly tested the effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the donor in encephalic death in reducing inflammation of organs to be transplanted. This study aims to evaluate the use of liraglutide in patients with brain death in relation to their ability to attenuate the inflammation induced by encephalic death by means of a randomized clinical trial.

Treatments tested

Liraglutide also known as placebo Drug

liraglutide 3mg 6/6 hours

Main thing measured	change inflammation
Sponsor	Hospital de Clinicas de Porto Alegre
Conditions studied	Brain Death
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03672812 ↗